SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Haleos Labs Ltd

BSE: 540679 NSE: HALEOSLABS ISIN: INE320X01016
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Haleos Labs Ltd belong to?
Haleos Labs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Haleos Labs Ltd a good quality company?
Haleos Labs Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Haleos Labs Ltd undervalued or overvalued?
Haleos Labs Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Haleos Labs Ltd a good buy now?
Haleos Labs Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Haleos Labs Ltd?
Haleos Labs Ltd revenue growth is 11.1% for FY-2025 , which is above its 5 year CAGR of 5.4% , indicating faster growth.
Q.2 Gross Profit margin of Haleos Labs Ltd?
Haleos Labs Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.9% for FY-2025 , which is above its 5 year median of 8.9% , indicating increasing margins.
Q.3 Operating Profit Margin of Haleos Labs Ltd?
Haleos Labs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 13.29% for FY-2025 , which is above its 5 year median of 11.45% indicating increasing margins.
Q.4 Net Profit Margin of Haleos Labs Ltd?
Haleos Labs Ltd Net Profit Margin is 6.41% for FY-2025 , is above with its 5 year median of 5.06%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 10.9 8.9
Operating Profit Margin 13.29 11.45
Net Profit Margin 6.41 5.06
Q.5 Return on Asset of Haleos Labs Ltd?
Haleos Labs Ltd Return on Asset is 5.95%, which is above its 5 year historical median of 5.19%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Haleos Labs Ltd?
Haleos Labs Ltd Return on equity is 11.45% for FY-2025 , which is above its historical median of 10.99%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Haleos Labs Ltd?
Haleos Labs Ltd Return on capital employed is 14.03% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Haleos Labs Ltd?
Haleos Labs Ltd Cash conversion cycle is 63 days, above its historical median of 46 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.02 1.07
ROE 11.45 10.99
ROCE 14.03 14.03
Cash Conversion Cycle 63 days 46 days
Q.9 Debt to Equity ratio of Haleos Labs Ltd?
Haleos Labs Ltd Debt-to-Equity ratio is 0.40 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Haleos Labs Ltd?
Haleos Labs Ltd Debt to cash flow from operations is 2.82 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Haleos Labs Ltd?
Promoters hold 72.11% of the Haleos Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Haleos Labs Ltd vs industry peers?
Haleos Labs Ltd revenue CAGR is 5.35% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 333.4 137.1
Gross Profit 36.3 15.1
Operating Profit 44 16
Net Profit 21 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.02 0.8
ROE 11.45 8.91
ROCE 14.03 11.59
Cash Conversion Cycle (days) 62.51 76

Valuation & price assessment

Q.1 Stock return of Haleos Labs Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 18.32% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - 18.3% 32.1% -9.2%
Q.3 Valuation ratios of Haleos Labs Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 21.56 17.52 40.28
Price to Book 1.85 1.83 2.77
Price to Sales 1.22 0.87 2.65
EV to EBITDA 10.73 8.58 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×